Impact of time to treatment on the effects of bivalirudin vs. glycoprotein IIb/IIIa inhibitors and heparin in patients undergoing primary percutaneous coronary intervention: insights from the HORIZONS-AMI trial. [electronic resource]
Producer: 20170726Description: 1144-1153 p. digitalISSN:- 1969-6213
- Aged
- Anticoagulants -- therapeutic use
- Antithrombins -- therapeutic use
- Cause of Death
- Drug Therapy, Combination
- Female
- Graft Occlusion, Vascular -- epidemiology
- Heparin -- therapeutic use
- Hirudins
- Humans
- Male
- Middle Aged
- Mortality
- Myocardial Infarction -- epidemiology
- Myocardial Revascularization -- statistics & numerical data
- Peptide Fragments -- therapeutic use
- Percutaneous Coronary Intervention -- methods
- Platelet Glycoprotein GPIIb-IIIa Complex -- antagonists & inhibitors
- Postoperative Complications -- epidemiology
- Recombinant Proteins -- therapeutic use
- Recurrence
- ST Elevation Myocardial Infarction -- therapy
- Stroke -- epidemiology
- Thrombosis -- epidemiology
- Time-to-Treatment -- statistics & numerical data
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.